Search results

Technologies 1

• Implantable Cancer Vaccine
  The implantable cancer vaccine is an aspirin-sized disc that is implanted under the skin and serves as an artificial lymph node, recruiting and training a patient's own immune cells to find and kill their cancer cells. It was validated in a Phase I clinical trial at the Wyss Institute, and is currently being developed by Novartis to treat melanoma.

Collaborations 1

• i3 Center: Biomaterials to Create T Cell Immunity
  Cancer immunologists and biological engineers are developing new biomaterials-based approaches to develop new anti-cancer immunotherapies for treatment-resistant cancers.

News 11

View all

• Press Release
  
  Biomaterial vaccines ward off broad range of bacterial infections and septic shock
  July 8, 2021
• Research Spotlights
  
  Harvard “Immuno-engineering to Improve Immunotherapy” (i3) Center at the Wyss Institute awards first grant to Dana-Farber cancer immunologist Eric Smith
  January 21, 2021
• Press Release
  
  A viable vaccine for tough tumors
  November 10, 2020